Fluidigm Urges Stockholders To Vote "FOR" ALL Proposals Related To $250M Strategic Capital Infusion TODAY

Author: Benzinga Newsdesk | March 21, 2022 07:04am

Fluidigm Corporation (NASDAQ:FLDM) today urged Fluidigm stockholders to vote “FOR” ALL proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”) at the Company’s upcoming Special Meeting of Stockholders (the “Special Meeting”). The Special Meeting is scheduled for March 25, 2022.

MAXIMIZE THE VALUE OF YOUR INVESTMENT BY VOTING “FOR” ALL PROPOSALS!

This transaction is the culmination of the Fluidigm Board’s comprehensive review of a wide range of options to maximize stockholder value. The investment by two leading life sciences and biotechnology-focused investors is expected to significantly advance the Company’s mission through new organic and inorganic growth initiatives while optimizing its cost structure. The $250 million capital infusion (inclusive of $25 million received in January 2022 in the form of convertible term loans) is expected to accelerate growth and innovation across the life science ecosystem as the Company pursues and consolidates complementary technologies with an improved balance sheet to create value for all stakeholders.

By voting “FOR” ALL proposals you are voting to:

• Optimize cost structure. The management team, led by Dr. Michael Egholm, will focus on cost structure optimization, including improvements in manufacturing.

• Achieve significantly greater breadth and scale. With a strong platform and deeply experienced management team, the Company expects to accelerate growth both organically and, importantly, inorganically to deliver breadth and scale.
   
• Leverage a larger menu to expanding customer base. The Company expects to invest in direct sales and marketing that expands its relationships deeper into the life science ecosystem, including the broader CRO and CMO service provider network.
   
• Accelerate growth in mass cytometry. With particular emphasis on CyTOF® and IMC platforms, the Company intends to simplify the design and execution of deep cell profiling, standardize sample analysis and significantly advance capabilities for novel therapeutic development.



 
• Realize and rationalize opportunities in targeted high profit areas within microfluidics. The Company expects to focus on targeted end-applications (e.g., proteomics, biomarker analysis) and key partnerships (e.g., Olink Bioscience) while rationalizing business processes and execution.

The Special Meeting will be held at the Genesis SSF Performing Arts Center, located at 1 Tower Place, South San Francisco, California 94080 on March 25, 2022, at 9 a.m. local time. Only stockholders of record at the close of business on February 18, 2022 are entitled to notice of, and to vote at, the Special Meeting.

Your vote is very important regardless of the number of shares of Common Stock that you own. Fluidigm stockholders who need assistance in completing the proxy card, need additional copies of the proxy materials, or have questions regarding the Special Meeting may contact Fluidigm’s proxy solicitor:

Alliance Advisors
200 Broadacres Drive
Bloomfield, NJ 07003
(833) 782-7142
FLDM@allianceadvisors.com

Posted In: FLDM